David Grayzel, M.D.
Partner, Atlas Venture
Dave is a partner at Atlas Venture where he has co-founded and led the growth of multiple biotech companies. He was co-founder and chief executive officer of Arteaus Therapeutics (acquired by Eli Lilly), and Annovation Biopharma (acquired by The Medicines Company), and a founding board member of Delinia (acquired by Celgene). Dave is a co-founder and board member of Surface Oncology, Cadent Therapeutics, and Q32 Bio. He also sits on the board of Xilio Therapeutics. Dave received a B.A. from Stanford University and an M.D. from Harvard Medical School.